BRISTOL MYERS SQUIBB CO SEC 10-Q Report

Bristol Myers Squibb Co. (BMS), a global biopharmaceutical company, has released its Form 10-Q report for the second quarter of 2025. The report provides a comprehensive overview of the company's financial performance and operational highlights, reflecting its ongoing efforts in the pharmaceutical industry. The key takeaways from the report include a slight increase in total revenues, strategic cost management, and significant developments in its product portfolio.

Financial Highlights

Total Revenues: $12,269 million, reflecting a slight increase from $12,201 million in the same period of 2024, driven by growth in the Growth Portfolio.

Cost of products sold: $3,372 million, representing an increase from $3,267 million in 2024, indicating higher production costs.

Selling, general and administrative expenses: $1,713 million, a decrease from $1,928 million in 2024, highlighting cost management efforts.

Research and development expenses: $2,580 million, down from $2,899 million in 2024, reflecting a reduction in R&D spending.

Earnings/(Loss) before income taxes: $1,773 million, an increase from $1,286 million in 2024, indicating improved operational efficiency.

Net earnings/(loss) attributable to BMS: $1,310 million, compared to $1,680 million in 2024, showing a decrease in net income.

Basic Earnings/(Loss) per common share: $0.64, down from $0.83 in 2024, reflecting the decrease in net earnings.

Diluted Earnings/(Loss) per common share: $0.64, consistent with the basic EPS, indicating no significant dilution effects.

Business Highlights

Revenue Segments: The Growth Portfolio, which includes products like Opdivo, Orencia, and Yervoy, generated $6,596 million in revenue for the three months ended June 30, 2025, showing a significant increase from $5,596 million in the same period in 2024. The Legacy Portfolio, including products like Eliquis and Revlimid, reported $5,673 million in revenue, down from $6,605 million in the previous year.

Geographical Performance: The United States remains the largest market, contributing $8,519 million to total revenues for the three months ended June 30, 2025, compared to $8,801 million in the same period in 2024. International markets, including Puerto Rico, contributed $3,481 million, up from $3,224 million in the previous year.

New Product Launches: In 2025, the company achieved multiple regulatory approvals, including Breyanzi for relapsed or refractory FL in the EU, Camzyos for symptomatic obstructive HCM in Japan, and Opdivo + Yervoy for various cancer treatments in the U.S. and EU.

Future Outlook: The company is focused on driving commercial execution in its key first-in-class and/or best-in-class marketed products, with potential for further expansion. The strategic focus remains on transformational medicines in oncology, hematology, immunology, cardiovascular, and neuroscience.

SEC Filing: BRISTOL MYERS SQUIBB CO [ BMY ] - 10-Q - Jul. 31, 2025